Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 17/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 17/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 17/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6623318 | 0.86 | ADORA3 (0.76) | ADORA3ADORA2AADORA1ADORA2BMAPT | |
| SCHEMBL6624470 | 0.81 | ADORA3 (0.76) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL6632936 | 0.81 | ADORA3 (0.72) | ADORA3ADORA2AADORA1ADORA2BMAPT | |
| SCHEMBL6624951 | 0.80 | ADORA3 (0.87) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL6624833 | 0.80 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL6636172 | 0.80 | ADORA3 (0.73) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL6655108 | 0.79 | ADORA3 (0.70) | ADORA3ADORA2AADORA1ADORA2BMAPT | |
| SCHEMBL6624650 | 0.79 | ADORA3 (0.72) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL6625227 | 0.79 | ADORA3 (0.85) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL6632547 | 0.78 | ADORA3 (0.71) | ADORA3ADORA2AADORA1ADORA2BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1430898-A1 | RECEPTOR ANTAGONIST | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-20040110826-A1 | Receptor Antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110826-A1 | Receptor Antagonists | ADRA2C, OPRL1, ADRB1 | ADORA3 85/4885ADORA2A 89/4885ADORA1 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.